{"title":"Department of Error","authors":"","doi":"10.1016/s0140-6736(24)02571-6","DOIUrl":null,"url":null,"abstract":"<em>Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.</em> Lancet <em>2024; <strong>404:</strong> 341–52</em>—In this Article, the unit for the dose of dexamethasone was corrected to mg in line 19 in paragraph one of the Procedures section. This correction has been made to the online version as of Nov 28, 2024.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(24)02571-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024; 404: 341–52—In this Article, the unit for the dose of dexamethasone was corrected to mg in line 19 in paragraph one of the Procedures section. This correction has been made to the online version as of Nov 28, 2024.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
